Development of M1 mAChR allosteric and bitopic ligands: Prospective therapeutics for the treatment of cognitive deficits

ACS Chemical Neuroscience

Volumn 4, Issue 7, 2013, Pages 1026-1048

  Davie, Briana J ^a   Christopoulos, Arthur ^a   Scammells, Peter J ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

allosteric ligands; Alzheimer's disease; cognitive deficits; M1 mAChR; memory; schizophrenia

Indexed keywords

LIGAND; MUSCARINIC M1 RECEPTOR; XANOMELINE;

ALLOSTERISM; BINDING SITE; COGNITIVE DEFECT; HUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; ALZHEIMER DISEASE; COGNITION DISORDERS; DRUG DEVELOPMENT; DRUG EFFECTS; METABOLISM; PHYSIOLOGY; DRUG EFFECT;

ALLOSTERIC REGULATION; ALZHEIMER DISEASE; COGNITION DISORDERS; DRUG DISCOVERY; HUMANS; LIGANDS; RECEPTOR, MUSCARINIC M1; SCHIZOPHRENIA;

EID: 84880357897     PISSN: None     EISSN: 19487193     Source Type: Journal    
DOI: 10.1021/cn400086m     Document Type: Review

References (144)

1. van Koppen, C. J. and Kaiser, B. (2003) Regulation of muscarinic acetylcholine receptor signaling Pharmacol. Ther. 98, 197-220
2. Canals, M., Sexton, P. M., and Christopoulos, A. (2011) Allostery in GPCRs: "MWC" revisited Trends Biochem. Sci. 36, 663-672
3. Caulfield, M. P. (1993) Muscarinic Receptors-Characterization, Coupling and Function Pharmacol. Ther. 58, 319-379
4. Nathanson, N. M. (2008) Synthesis, trafficking and localization of muscarinic acetylcholine receptors Pharmacol. Ther. 119, 33-43
5. 1 Muscarinic Agonists Target Major Hallmarks of Alzheimer's Disease-The Pivotal Role of Brain M1 Receptors Neurodegener. Dis. 5, 237-240
6. Langmead, C. J., Watson, J., and Reavill, C. (2008) Muscarinic acetylcholine receptors as CNS drug targets Pharmacol. Ther. 117, 232-243
7. Xu, Y., Yan, J., Zhou, P., Li, J., Gao, H., Xia, Y., and Wang, Q. (2012) Neurotransmitter receptors and cognitive dysfunction in Alzheimer's disease and Parkinson's disease Prog. Neurobiol. 97, 1-13
8. Wess, J. (2004) Muscarinic Acetylcholine Receptor Knockout Mice: Novel Phenotypes and Clinical Implications Annu. Rev. Pharmacol. Toxicol. 44, 423-450
9. Bodick, N. C., Offen, W. W., Levey, A. I., Cutler, N. R., Gauthier, S. G., Satlin, A., Shannon, H. E., Tollefson, G. D., Rasmussen, K., Bymaster, F. P., Hurley, D. J., Potter, W. Z., and Paul, S. M. (1997) Effects of Xanomeline, a Selective Muscarinic Receptor Agonist, on Cognitive Function and Behavioral Symptoms in Alzheimer Disease Arch. Neurol. 54, 465-473
10. Digby, G. J., Shirey, J. K., and Conn, P. J. (2010) Allosteric activators of muscarinic receptors as novel approaches for treatment of CNS disorders Mol. BioSyst. 6, 1345-1354
11. Bartus, R. T., Dean, R. L., Beer, B., and Lippa, A. S. (1982) The Cholinergic Hypothesis of Geriatric Memory Dysfunction Science 217, 408-417
12. Whitehouse, P. J., Price, D. L., Struble, R. G., Clark, A. W., Coyle, J. T., and Delon, M. R. (1982) Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain Science 215, 1237-1239
13. Francis, P. T., Palmer, A. M., Snape, M., and Wilcock, G. K. (1999) The cholinergic hypothesis of Alzheimer's disease: a review of progress J. Neurol. Neurosurg. Psychiatry 66, 137-147
14. Giacobini, E. (2000) Cholinesterase Inhibitors Stabilize Alzheimer's Disease Ann. N.Y. Acad. Sci. 920, 321-327
15. Mirza, N. R., Peters, D., and Sparks, R. G. (2003) Xanomeline and the Antipsychotic Potential of Muscarinic Receptor Subtype Selective Agonists CNS Drug Rev. 9, 159-186
16. Bymaster, F. P., Whitesitt, C. A., Shannon, H. E., DeLapp, N., Ward, J. S., Calligaro, D. O., Shipley, L. A., Buelke-Sam, J. L., Bodick, N. C., Farde, L., Sheardown, M. J., Olesen, P. H., Hansen, K. T., Suzdak, P. D., Swedberg, M. D. B., Sauerberg, P., and Mitch, C. H. (1997) Xanomeline: A Selective Muscarinic Agonist for the Treatment of Alzheimer's Disease Drug Dev. Res. 40, 158-170
17. 5 Muscarinic Receptor Knockout Mice as Novel Tools to Delineate the Physiological Roles of the Muscarinic Cholinergic System Neurochem. Res. 28, 437-442
18. 4 preferring muscarinic cholinergic receptor agonist, produces antipsychotic-like activity in rats and mice Schizophr. Res. 42, 249-259
19. Shekhar, A., Potter, W. Z., Lightfoot, J., Lienemann, J., Dube, S., Mallinckrodt, C., Bymaster, F. P., McKinzie, D. L., and Felder, C. C. (2008) Selective Muscarinic Receptor Agonist Xanomeline as a Novel Treatment Approach for Schizophrenia Am. J. Psychiatry 165, 1033-1039
20. 1 receptor knockout mice Eur. J. Pharmacol. 603, 147-149
21. 4 muscarinic receptors regulate the dynamics of cholinergic and dopaminergic neurotransmission: relevance to the pathophysiology and treatment of related central nervous system pathologies FASEB J. 18, 1410-1427
22. 5 using microphysiometry Br. J. Pharmacol. 126, 1620-1624
23. Farrell, M. and Roth, B. L. (2010) Allosteric Antipsychotics: M4Muscarinic Potentiatiors as Novel Treatments for Schizophrenia Neuropsychopharmacology 35, 851-852
24. 1 receptor signaling correlates with loss of protein kinase C activity and glutamatergic deficit in Alzheimer's disease Neurobiol. Aging 28, 1381-1387
25. Fisher, A. (2012) Cholinergic modulation of amyloid precursor protein processing with emphasis on M1 muscarinic receptor: perspectives and challenges in treatment of Alzheimer's disease J. Neurochem. 120, 22-33
26. Marino, M. J., Rouse, S. T., Levey, A. I., Potter, L. T., and Conn, P. J. (1998) Activation of the genetically defined m1 muscarinic receptor potentiates N -methyl- d -aspartate (NMDA) receptor currents in hippocampal pyramidal cells Proc. Natl. Acad. Sci. U.S.A. 95, 11465-11470
27. Collingridge, G. L., Volianskis, A., Bannister, N., France, G., Hanna, L., Mercier, M., Tidball, P., Fang, G., Irvine, M. W., Costa, B. M., Monaghan, D. T., Bortolotto, Z. A., Molnar, E., Lodge, D., and Jane, D. E. (2013) The NMDA receptor as a target for cognitive enhancement Neuropharmacology 64, 13-26
28. Davies, P. and Maloney, A. J. F. (1976) Selective Loss of Central Cholinergic Neurons in Alzheimer's Disease Lancet 2, 1403
29. Flynn, D. D., Ferrari-DiLeo, G., Mash, D. C., and Levey, A. I. (1995) Differential Regulation of Molecular Subtypes of Muscarinic Receptors in Alzheimer's Disease J. Neurochem. 64, 1888-1891
30. 1 receptor concentration increases without a concomitant change in function in Alzheimer's disease J. Chem. Neuroanat. 40, 63-70
31. Turner, P. R., O'Connor, K., Tate, W. P., and Abraham, W. C. (2003) Roles of amyloid precursor protein and its fragments in regulating neural activity, plasticity and memory Prog. Neurobiol. 70, 1-32
32. 42 in patients with Alzheimer's disease Amyloid 10, 1-6
33. Fisher, A., Michaelson, D. M., Brandeis, R., Haring, R., Chapman, S., and Pittel, Z. (2000) M1Muscarinic Agonists as Potential Disease-Modifying Agents in Alzheimer's Disease: Rationale and Perspectives Ann. N.Y. Acad. Sci. 920, 315-320
34. Buxbaum, J. D., Gandy, S. E., Cicchetti, P., Ehrlich, M. E., Czernik, A. J., Fracasso, R. P., Ramabhadran, T. V., Unterbeck, A. J., and Greengard, P. (1990) Processing of Alzheimer beta/A4 amyloid precursor protein: Modulation by agents that regulate protein phosphorylation Proc. Natl. Acad. Sci. U.S.A. 87, 6003-6006
35. 1 Receptors Play a Central Role in Modulating AD-like Pathology in Transgenic Mice Neuron 49, 671-682
36. 2 Dopamine Receptor Occupancy in Patients Treated With Classical Neuroleptics and Clozapine Arch. Gen. Psychiatry 49, 538-544
37. Serretti, A., De Ronchi, D., Lorenzi, C., and Berardi, D. (2004) New Antipsychotics and Schizophrenia: A Review on Efficacy and Side Effects Curr. Med. Chem. 11, 343-358
38. DeLeon, A., Patel, N. C., and Crismon, M. L. (2004) Aripiprazole: A Comprehensive Review of Its Pharmacology, Clinical Efficacy, and Tolerability Clin. Ther. 26, 649-666
39. Minzenberg, M. J. and Carter, C. S. (2012) Developing treatments for impaired cognition in schizophrenia Trends Cognit. Sci. 16, 35-42
40. Felder, C. C., Bymaster, F. P., and DeLapp, N. (2000) Therapeutic Opportunities for Muscarinic Receptors in the Central Nervous System J. Med. Chem. 43, 4333-4353
41. Crook, J. M., Tomaskovic-Crook, E., Copolov, D. L., and Dean, B. (2000) Decreased Muscarinic Receptor Binding in Subjects with Schizophrenia: A Study of the Human Hippocampal Formation Biol. Psychiatry 48, 381-388
42. Crook, J. M., Tomaskovic-Crook, E., Copolov, D. L., and Dean, B. (2001) Low Muscarinic Receptor Binding in Prefrontal Cortex From Subjects With Schizophrenia: A Study of Brodmann's Areas 8, 9, 10 and 46 and the Effects of Neuroleptic Drug Treatment Am. J. Psychiatry 158, 918-925
43. Raedler, T. J., Bymaster, F. P., Tandon, R., Copolov, D., and Dean, B. (2007) Towards a muscarinic hypothesis of schizophrenia Mol. Psychiatry 12, 232-246
44. 1 agonists in the treament of Alzheimer's disease Expert Opin. Invest. Drug 9, 2259-2267
45. Flynn, D. D., Weinstein, D. A., and Mash, D. C. (1991) Loss of High-Affinity Agonist Binding to M1Muscarinic Receptors in Alzheimer's Disease: Implications for the Failure of Cholinergic Replacement Therapies Ann. Neurol. 29, 256-262
46. Langmead, C. J. and Christopoulos, A. (2006) Allosteric agonists of 7TM receptors: expanding the pharmacological toolbox Trends Pharmacol. Sci. 27, 475-481
47. Kenakin, T. P. (2012) Biased signalling and allosteric machines: new vistas and challenges for drug discovery Br. J. Pharmacol. 165, 1659-1669
48. May, L. T., Leach, K., Sexton, P. M., and Christopoulos, A. (2007) Allosteric Modulation of G Protein-Coupled Receptors Annu. Rev. Pharmacol. Toxicol. 47, 1-51
49. Dong, B. J. (2005) Cinacalcet: An Oral Calcimimetic Agent for the Management of Hyperparathyroidism Clin. Ther. 27, 1725-1751
50. Garcia-Perez, J., Rueda, P., Staropoli, I., Kellenberger, E., Alcami, J., Arenzana-Seisdedos, F., and Lagane, B. (2011) New Insights into the Mechanisms whereby Low Molecular Weight CCR5 Ligands Inhibit HIV-1 Infection J. Biol. Chem. 286, 4978-4990
51. Ehlert, F. J., Roeske, W. R., Gee, K. W., and Yamamura, H. I. (1983) An Allosteric Model For Benzodiazepine Receptor Function Biochem. Pharmacol. 32, 2375-2383
52. Christopoulos, A. (2002) Allosteric Binding Sites On Cell-Surface Receptors: Novel Targets For Drug Discovery Nat. Rev. Drug Discovery 1, 198-210
53. Conn, P. J., Jones, C. K., and Lindsley, C. W. (2009) Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders Trends Pharmacol. Sci. 30, 148-155
54. Kenakin, T. (2005) New Concepts In Drug Discovery: Collateral Efficacy And Permissive Antagonism Nat. Rev. Drug Discovery 4, 919-927
55. Kenakin, T. (2003) Ligand-selective receptor conformations revisited: the promise and the problem Trends Pharmacol. Sci. 24, 346-354
56. Keov, P., Sexton, P. M., and Christopoulos, A. (2011) Allosteric modulation of G protein-coupled receptors: A pharmacological perspective Neuropharmacology 60, 24-35
57. 4 Muscarinic Acetylcholine Receptor Allosteric Modulator with Potential Antipsychotic Properties Neuropsychopharmacology 35, 855-869
58. Canals, M., Lane, J. R., Wen, A., Scammells, P. J., Sexton, P. M., and Christopoulos, A. (2012) A Monod-Wyman-Changeux Mechanism Can Explain G Protein-coupled Receptor (GPCR) Allosteric Modulation J. Biol. Chem. 287, 650-659
59. Palczewski, K., Kumasaka, T., Hori, T., Behnke, C. A., Motoshima, H., Fox, B. A., Le Trong, I., Teller, D. C., Okada, T., Stenkamp, R. E., Yamamoto, M., and Miyano, M. (2000) Crystal Structure of Rhodopsin: A G Protein-Coupled Receptor Science 289, 739-745
60. 2 adrenergic G-protein-coupled receptor Nature 450, 383-388
61. 2A Adenosine Receptor Bound to an Antagonist Science 322, 1211-1217
62. Strotmann, R., Schrock, K., Boselt, I., Staubert, C., Russ, A., and Schoneberg, T. (2011) Evolution of GPCR: Change and continuity Mol. Cell. Endocrinol. 331, 170-178
63. Haga, K., Kruse, A. C., Asada, H., Yurugi-Kobayashi, T., Shiroishi, M., Zhang, C., Weis, W. I., Okada, T., Kobilka, B. K., Haga, T., and Kobayashi, T. (2012) Structure of the human M2 muscarinic acetylcholine receptor bound to an antagonist Nature 482, 547-552
64. Kruse, A. C., Hu, J., Pan, A. C., Arlow, D. H., Rosenbaum, D. M., Rosemond, E., Green, H. F., Liu, T., Chae, P. S., Dror, R. O., Shaw, D. E., Weis, W. I., Wess, J., and Kobilka, B. K. (2012) Structure and dynamics of the M3 muscarinic acetylcholine receptor Nature 482, 552-559
65. Hulme, E. C., Birdsall, N. J. M., and Buckley, N. J. (1990) Muscarinic Receptor Subtypes Annu. Rev. Pharmacol. Toxicol. 30, 633-673
66. Spalding, T. A., Birdsall, N. J. M., Curtis, C. A. M., and Hulme, E. C. (1994) Acetylcholine Mustard Labels the Binding Site Aspartate in Muscarinic Acetylcholine Receptors J. Biol. Chem. 269, 4092-4097
67. Goodwin, J. A., Hulme, E. C., Langmead, C. J., and Tehan, B. G. (2007) Roof and Floor of the Muscarinic Binding Pocket: Variations in the Binding Modes of Orthosteric Ligands Mol. Pharmacol. 72, 1484-1496
68. Ellis, J. (1997) Allosteric Binding Sites on Muscarinic Receptors Drug Dev. Res. 40, 193-204
69. Wess, J. (2005) Allosteric Binding Sites on Muscarinic Acetylcholine Receptors Mol. Pharmacol. 68, 1506-1509
70. Gnagey, A. L., Seidenberg, M., and Ellis, J. (1999) Site-Directed Mutagenesis Reveals Two Epitopes Involved in the Subtype Selectivity of the Allosteric Interactions of Gallamine at Muscarinic Acetylcholine Receptors Mol. Pharmacol. 56, 1245-1253
71. 3H]Scopolamine and Acetylcholine at Muscarinic Receptor Subtypes: Identification of a Second Allosteric Site Mol. Pharmacol. 58, 194-207
72. Birdsall, N. J. M., Lazareno, S., Popham, A., and Saldanha, J. (2001) Multiple allosteric sites on muscarinic receptors Life Sci. 68, 2517-2524
73. Lazareno, S., Popham, A., and Birdsall, N. J. M. (2002) Analogs of WIN 62,577 Define a Second Allosteric Site on Muscarinic Receptors Mol. Pharmacol. 62, 1492-1505
74. 1 muscarinic acetylcholine receptor and its implications for drug design Bioorg. Med. Chem. Lett. 16, 1217-1220
75. Kenakin, T. and Christopoulos, A. (2013) Signalling bias in new drug discovery: detection, quantification and therapeutic impact Nat. Rev. Drug Discovery 12, 205-216
76. Valant, C., Felder, C. C., Sexton, P. M., and Christopoulos, A. (2012) Probe Dependence in the Allosteric Modulation of a G Protein-Coupled Receptor: Implications for Detection and Validation of Allosteric Ligand Effects Mol. Pharmacol. 81, 41-52
77. 4 receptor as an approach to treating schizophrenia Proc. Natl. Acad. Sci. U.S.A. 105, 10978-10983
78. 4 muscarinic acetylcholine receptor Br. J. Pharmacol. 162, 1659-1670
79. 2 Receptors J. Pharmacol. Exp. Ther. 282, 278-285
80. 2 Muscarinic Acetylcholine Receptors Mol. Pharmacol. 72, 463-476
81. Antony, J., Kellershohn, K., Mohr-Andra, M., Kebig, A., Prilla, S., Muth, M., Heller, E., Disingrini, T., Dallanoce, C., Bertoni, S., Schrobang, J., Trankle, C., Kostenis, E., Christopoulos, A., Holtje, H.-D., Barocelli, E., De Amici, M., Holzgrabe, U., and Mohr, K. (2009) Dualsteric GPCR targeting: a novel route to binding and signaling pathway selectivity FASEB J. 23, 442-450
82. Lane, J. R., Sexton, P. M., and Christopoulos, A. (2013) Bridging the gap: bitopic ligands of G-protein-coupled receptors Trends Pharmacol. Sci. 34, 59-66
83. Valant, C., Sexton, P. M., and Christopoulos, A. (2009) Orthosteric/Allosteric Bitopic Ligands-Going Hybrid at GPCRs Mol. Interventions 9, 125-135
84. Valant, C., Gregory, K. J., Hall, N. E., Scammells, P. J., Lew, M. J., Sexton, P. M., and Christopoulos, A. (2008) A Novel Mechanism of G Protein-coupled Receptor Functional Selectivity-Muscarinic Partial Agonist McN-A-343 As A Bitopic Orthosteric/Allosteric Ligand J. Biol. Chem. 283, 29312-29321
85. Birdsall, N. J. M., Burgen, A. S. V., Hulme, E. C., Stockton, J. M., and Zigmond, M. J. (1983) The effect of McN-A-343 on muscarinic receptors in the cerebral cortex and heart Br. J. Pharmacol. 78, 257-259
86. Lazareno, S. and Birdsall, N. J. M. (1995) Detection, Quantitation, and Verification of Allosteric Interactions of Agents with Labeled and Unlabeled Ligands at G Protein-Coupled Receptors: Interactions of Strychnine and Acetylcholine at Muscarinic Receptors Mol. Pharmacol. 48, 362-378
87. Birdsall, N. J. M., Farries, T., Gharagozloo, P., Kobayashi, S., Kuonen, D., Lazareno, S., Popham, A., and Sugimoto, M. (1997) Selective Allosteric Enhancement of the Binding and Actions of Acetylcholine at Muscarinic Receptor Subtypes Life Sci. 60, 1047-1052
88. 1 muscarinic acetylcholine receptor achieved by allosteric potentiation Proc. Natl. Acad. Sci. U.S.A. 106, 15950-15955
89. 1 Muscarinic Acetylcholine Receptor J. Neurosci. 21, 5239-5250
90. 1 receptors Neurosci. Lett. 278, 61-64
91. 1 Muscarinic Acetylcholine Receptor Increases Activity of Medial Prefrontal Cortical Neurons and Restores Impairments in Reversal Learning J. Neurosci. 29, 14271-14286
92. Caruana, D. A., Warburton, E. C., and Bashir, Z. I. (2011) Induction of Activity-Dependent LTD Requires Muscarinic Receptor Activation in Medial Prefrontal Cortex J. Neurosci. 31, 18464-18478
93. 1 receptor positive allosteric modulators to improve memory via enhancement of brain cholinergic communication Eur. J. Pharmacol. 697, 73-80
94. Chambon, C., Wegener, N., Gravius, A., and Danysz, W. (2011) A new automated method to assess the rat recognition memory: Validation of the method Behav. Brain Res. 222, 151-157
95. Reichel, A. (2006) The Role of Blood-Brain Barrier Studies in the Pharmaceutical Industry Curr. Drug Metab. 7, 183-203
96. 1 positive allosteric modulators Bioorg. Med. Chem. Lett. 20, 531-536
97. 1 Allosteric Muscarinic Receptor Modulators ACS Med. Chem. Lett. 1, 263-267
98. Kuduk, S. D., Chang, R. K., Di Marco, C. N., Ray, W. J., Ma, L., Wittman, M., Seager, M. A., Koeplinger, K. A., Thompson, C. D., Hartman, G. D., and Bilodeau, M. T. (2011) Quinolizidinone carboxylic acid selective M1 allosteric modulators: SAR in the piperidine series Bioorg. Med. Chem. Lett. 21, 1710-1715
99. 1 positive allosteric modulators Bioorg. Med. Chem. Lett. 20, 2533-2537
100. 1 positive allosteric modulators with reduced plasma protein binding Bioorg. Med. Chem. Lett. 20, 657-661
101. 1 positive allosteric modulators Bioorg. Med. Chem. Lett. 20, 1334-1337
102. 1 positive allosteric modulators Bioorg. Med. Chem. Lett. 21, 2769-2772
103. 1 positive allosteric modulators Bioorg. Med. Chem. Lett. 20, 2538-2541
104. 1 Positive Allosteric Modulators ACS Med. Chem. Lett. 3, 1070-1074
105. Uslaner, J. M., Eddins, D., Puri, V., Cannon, C. E., Sutcliffe, J., Chew, C. S., Pearson, M., Vivian, J. A., Chang, R. K., Ray, W. J., Kuduk, S. D., and Wittmann, M. (2013) The muscarinic M1 receptor positive allosteric modulator PQCA improves cognitive measures in rat, cynomolgus macaque, and rhesus macaque Psychopharmacology 225, 21-30
106. 1 allosteric ligands: a patent review Expert Opin. Ther. Pat. 22, 1385-1398
107. 1 Muscarinic Receptors Reveals Multiple Modes of Activity Mol. Pharmacol. 75, 577-588
108. 1 PAM Bioorg. Med. Chem. Lett. 20, 1972-1975
109. 5 PAM Bioorg. Med. Chem. Lett. 20, 558-562
110. 1 PAM ML137: Continued optimization of an MLPCN probe molecule Bioorg. Med. Chem. Lett. 23, 412-416
111. 1 PAM ML137: the continued optimization of an MLPCN probe molecule Bioorg. Med. Chem. Lett. 23, 1860-1864
112. 1 positive allosteric modulator (PAM): The development of ML169, an MLPCN probe Bioorg. Med. Chem. Lett. 21, 2697-2701
113. 1 Positive Allosteric Modulator ML169 ACS Chem. Neurosci. 3, 884-895
114. Spalding, T. A., Trotter, C., Skjaerbaek, N., Messier, T. L., Currier, E. A., Burstein, E. S., Li, D., Hacksell, U., and Brann, M. R. (2002) Discovery of an Ectopic Activation Site on the M1 Muscarinic Receptor Mol. Pharmacol. 61, 1297-1302
115. 1 Muscarinic Acetylcholine Receptor Mol. Pharmacol. 78, 94-104
116. 1 Receptor: Direct Pharmacological Evidence That AC-42 Is an Allosteric Agonist Mol. Pharmacol. 69, 236-246
117. 1 Muscarinic Receptor Agonists AC-42, AC-260584, Clozapine, and N -Desmethylclozapine: Evidence for Three Distinct Modes of Receptor Activation Mol. Pharmacol. 70, 1974-1983
118. 1 muscarinic receptor allosteric agonists Soc. Neurosci. Abstr. 30, 846.16
119. 1 Muscarinic Acetylcholine Receptor Orthosteric and Allosteric Agonists J. Pharmacol. Exp. Ther. 327, 365-374
120. 1 Muscarinic Acetylcholine Receptor Internalization and Down-regulation J. Pharmacol. Exp. Ther. 331, 1086-1095
121. 1 Muscarinic Acetylcholine Receptors Mol. Pharmacol. 75, 331-341
122. 1 muscarinic receptor allosteric agonist, improves cognitive performance in an animal model Neuropharmacology 58, 365-373
123. 1 Receptor Agonist AC-260584 Behav. Neurosci. 122, 570-575
124. 1 muscarinic receptor agonist, 77-LH-28-1 Br. J. Pharmacol. 154, 1104-1115
125. 1 Receptors Is Mediated by Inhibition of SK Channels Neuron 68, 948-963
126. Kuroki, T., Nagao, N., and Nakahara, T. (2008) Neuropharmacology of second-generation antipsychotic drugs: a validity of the serotonin-dopamine hypothesis Prog. Brain Res. 172, 199-212
127. Sur, C., Mallorga, P. J., Wittmann, M., Jacobson, M. A., Pascarella, D., Williams, J. B., Brandish, P. E., Pettibone, D. J., Scolnick, E. M., and Conn, P. J. (2003) N -Desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N -methyl- d -aspartate receptor activity Proc. Natl. Acad. Sci. U.S.A. 100, 13674-13679
128. 1 receptor Neuropharmacology 58, 1206-1214
129. 1 Muscarinic Acetylcholine Receptor Regulates Amyloid Processing and Produces Antipsychotic-Like Activity in Rats J. Neurosci. 28, 10422-10433
130. 1 allosteric agonist TBPB. Part I: Exploration of alternative benzyl
131. Miller, N. R., Daniels, R. N., Bridges, T. M., Brady, A. E., Conn, P. J., and Lindsley, C. W. (2008) Synthesis and SAR of analogs of the M1 allosteric agonist TBPB. Part II: Amides, sulfonamides and ureas-The effect of capping the distal basic piperidine nitrogen Bioorg. Med. Chem. Lett. 18, 5443-5447
132. 1 allosteric agonism and result in pan -mAChR orthosteric antagonism Bioorg. Med. Chem. Lett. 23, 223-227
133. 1 Receptor Function in the Central Nervous System ACS Chem. Neurosci. 1, 104-121
134. 1 agonist derived from the MLPCN probe ML071 Bioorg. Med. Chem. Lett. 21, 6451-6455
135. 1 muscarinic acetylcholine receptor Bioorg. Med. Chem. Lett. 22, 3467-3472
136. 1 Muscarinic Acetylcholine Receptors Induce Brain Region-Specific Responses That Correspond with Behavioural Effects in Animal Models J. Neurosci. 32, 8532-8544
137. 1 Agonist VU0364572 Reveals Molecular Switches in Pharmacology and a Bitopic Binding Mode ACS Chem. Neurosci. 3, 1025-1036
138. 1 Receptor Agonist with Unprecedented Selectivity and Procognitive Potential J. Med. Chem. 53, 6386-6397
139. 1 receptor ligands with putative antipsychotic and pro-cognitive potential Bioorg. Med. Chem. Lett. 22, 5134-5140
140. 1 agonists. Part I: Identification, synthesis, and initial SAR Bioorg. Med. Chem. Lett. 20, 3540-3544
141. 1 agonists. Part II: Further optimization and profiling Bioorg. Med. Chem. Lett. 20, 3545-3549
142. 1 mAChR Agonists ACS Med. Chem. Lett. 1, 244-248
143. 1 agonists Bioorg. Med. Chem. Lett. 20, 5434-5438
144. 1 receptor allosteric agonist GSK1034702 improves episodic memory in humans in the nicotine abstinence model of cognitive dysfunction Int. J. Neuropsychopharmacol. 16, 721-731-731